Humana jumps as Medicare Advantage rate outlook improves and analysts refresh targets

Humana Inc. (HUM) is up 5.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is renewed optimism around Humana’s Medicare Advantage profit outlook after the U.S. government finalized a higher-than-feared Medicare Advantage payment update for the next cycle. The move also appears to be reinforced by follow-on analyst note activity that lifted price targets as investors recalibrated earnings expectations.

Details:

Federal regulators finalized the Calendar Year 2027 Medicare Advantage and Part D Rate Announcement, projecting an average payment increase of 2.48% (over $13 billion) to MA plans in 2027.

The final update was a meaningful improvement versus the earlier proposal that implied roughly flat payment growth, helping ease near-term policy pressure that had weighed on managed-care valuations.

With Humana’s business heavily exposed to Medicare Advantage economics, any perceived improvement in benchmark payments and policy details can quickly change expectations for 2027 margins and benefit design flexibility.

Recent analyst updates have also lifted Humana price targets (while in some cases maintaining a neutral/hold stance), which can add incremental support on days when sentiment turns.

Sources:

Centers for Medicare & Medicaid Services, StockAnalysis, Benzinga

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HUM Insider Trading Activity

$HUM insiders have traded $HUM stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $HUM stock by insiders over the last 6 months:

SANJAY K SHETTY (President, CenterWell) purchased 810 shares for an estimated $150,016

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

EARLY ACCESS

Receive HUM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$HUM Hedge Fund Activity

We have seen 326 institutional investors add shares of $HUM stock to their portfolio, and 507 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 3,514,521 shares (-74.8%) from their portfolio in Q4 2025, for an estimated $900,174,263
CAPITAL INTERNATIONAL INVESTORS added 3,097,571 shares (+113.9%) to their portfolio in Q4 2025, for an estimated $793,380,860
WELLINGTON MANAGEMENT GROUP LLP added 1,170,387 shares (+4481.7%) to their portfolio in Q4 2025, for an estimated $299,771,222
FRANKLIN RESOURCES INC added 1,131,893 shares (+914.5%) to their portfolio in Q4 2025, for an estimated $289,911,754
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 1,008,514 shares (+28.9%) to their portfolio in Q4 2025, for an estimated $258,310,690
SLATE PATH CAPITAL LP added 953,000 shares (+inf%) to their portfolio in Q4 2025, for an estimated $244,091,890
EAGLE CAPITAL MANAGEMENT LLC removed 711,094 shares (-17.9%) from their portfolio in Q4 2025, for an estimated $182,132,506

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$HUM Congressional Stock Trading

Members of Congress have traded $HUM stock 5 times in the past 6 months. Of those trades, 1 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $HUM stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 02/10.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. sold up to $15,000 on 11/12.
REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 1 purchase worth up to $15,000 on 10/30 and 2 sales worth up to $30,000 on 10/31, 10/30.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$HUM Analyst Ratings

Wall Street analysts have issued reports on $HUM in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Jefferies issued a "Buy" rating on 12/05/2025

To track analyst ratings and price targets for $HUM, check out Quiver Quantitative's $HUM forecast page.

$HUM Price Targets

Multiple analysts have issued price targets for $HUM recently. We have seen 12 analysts offer price targets for $HUM in the last 6 months, with a median target of $195.0.

Here are some recent targets:

David Macdonald from Truist Securities set a target price of $220.0 on 04/13/2026
Elizabeth Suzuki from Evercore ISI Group set a target price of $195.0 on 04/08/2026
Stephen Baxter from Wells Fargo set a target price of $227.0 on 04/07/2026
Andrew Mok from Barclays set a target price of $176.0 on 02/25/2026
Nathan Rich from Goldman Sachs set a target price of $158.0 on 02/17/2026
Ryan Langston from TD Cowen set a target price of $173.0 on 02/13/2026
David Windley from Jefferies set a target price of $235.0 on 02/12/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.